Recurrence of Positive SARS-CoV-2 RNA in a COVID-19 Patient: Two Case Reports from Saudi Arabia

Sarah Alturaif
SmartLab

Remaaz Alharbi
SmartLab

Waleed Alqurashi
University of Ottawa

Abdulaziz Alsadoon
SmartLab

Meshari Alabdullatif (Meshari249@gmail.com)
SmartLab
https://orcid.org/0000-0003-3354-6221

Case Report

Keywords: SARS-CoV-2, COVID19, Reinfection, Saudi Arabia

DOI: https://doi.org/10.21203/rs.3.rs-86920/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
Abstract

Background The rapid spread of the COVID-19 pandemic which took a place in Wuhan, China and diffused globally required the international public health to take a coordinated international response. As other coronaviruses were described, SARS-CoV-2 was thought to be an immunizing, monophasic disease. Herein, we reported first two COVID-19 cases registered in Saudi Arabia whose nasopharyngeal swabs turned positive for SARS-CoV-2 ribonucleic acid (RNA) after recovery.

Case presentation First patient who is symptomatic with recurrence of positive SARS-CoV-2 RNA occurred 115 days after the first symptomatic infection and did not develop protective immune response. Second patient who is asymptomatic during the recurrence of positive SARS-CoV-2 RNA occurred 60 days after the first symptomatic infection in an apparently immunocompetent patient.

Conclusion These findings highlight the recurrence of positive SARS-CoV-2 after recovery even if SARS-CoV-2 antibodies were developed.

Background

Since the fast expansion of the ongoing global pandemic Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in December 2019, the number of Coronavirus disease (COVID-19) cases have exceeded 27 million worldwide [1]. Saudi Arabia was among the impacted countries that reported the first case of COVID-19 on March 2, 2020. By September 8, 2020, the Ministry of Health (MOH) reported over 322,000 positive cases, with 4137 deaths and 298,246 recoveries [2].

COVID-19 is a respiratory illness, person to person contact, and respiratory droplets are the primary route of infection. When the pandemic first started, it was thought to be an immunizing, non-relapsing disease [3]. However, in some countries, there have been reports of rare suspected cases of COVID-19 reinfection [4]. Herein, we reported two COVID-19 cases registered in Saudi Arabia with recurrence of positive SARS-CoV-2 ribonucleic acid (RNA).

Case Presentation

First case

Patient 1 is a 23-year old healthy male, with no underlying medical conditions, who had a nasopharyngeal (NP) swab collected on April 13 using a viral transport media (VTM). As recommended by the Saudi Ministry of Health, the diagnostic testing for SARS-CoV-2 was performed by real-time reverse transcriptase-polymerase chain reaction (RT-PCR) using at least one confirmatory target, in addition to the screening targets [5]. The RT-PCR test was done as a standard infection control procedure after the patient arrived from a trip abroad. The test result was positive and confirmed by the National Health Laboratory (NHL; Table 1). Two days later, the patient started complaining from joints pain, mild headache, and diarrhea. According to the Saudi Ministry of Health guidelines for COVID-19 positive patients, the local
health authorities urged him to self-isolate until his symptoms resolve, and the subsequent test is negative [6]. He received no prescription medications during his quarantine period. To follow up, on April 20 and 25 two NP swabs were collected for RT-PCR assay test at two different laboratories, and both results were negative. As a result, the patient resumed his normal life. Just over three months later (August 6), he developed the following symptoms: moderate headache, fatigue, sore throat, and diarrhea. He suspected reinfection due to close contact with COVID19 patient and performed two SARS-CoV-2 RT-PCR tests at two different laboratories; both were positive. The symptoms were subjectively more intense this time and lasted for three days. A follow-up and confirmatory tests were carried out on August 13 and 16, respectively, and both yielded negative results. For further investigations, a SARS-CoV-2 IgG assay was conducted (August 16) for the detection of SARS-CoV-2 antibodies development, and it came out negative with a titer of 0.16 AU/mL (Reference value < 0.7 AU/mL) indicating a possible non-protective immune response [7].
Table 1
Timelines and testing results of the SARS-CoV-2 recurrence cases

| Patient | Age (years) | Sex | Timelines | Symptoms                     | NP a Swab | Confirmation | Serology (SARS-CoV-2 IgG) |
|---------|-------------|-----|-----------|------------------------------|-----------|--------------|---------------------------|
| 1       | 23          | Male| April 13  | Arthralgia                   | Positive  | Positive     | (NHL d)                  |
|         |             |     |           | Mild headache                |           |              |                           |
|         |             |     |           | Diarrhea                     |           |              |                           |
|         |             |     | April 20  | No                           | Negative  | Negative     | (DL e)                   |
|         |             |     |           |                             |           |              |                           |
|         |             |     | April 25  | No                           | Negative  | Negative     | (DL)                     |
|         |             |     |           |                             |           |              |                           |
|         |             |     | August 6  | Moderate headache            | Positive  | Positive     | (DL)                     |
|         |             |     |           | Fatigue                      |           |              |                           |
|         |             |     |           | Sore throat                  |           |              |                           |
|         |             |     |           | Diarrhea                     |           |              |                           |
|         |             |     | August 13 | No                           | Negative  |              |                           |
|         |             |     | August 16 | No                           | Negative  |              |                           |

Patient 2

|         | 59          | Male| June 16   | Fever Arthralgia, Myalgia   | Positive  | Positive     | (NHL)                    |
|         |             |     |           | Fatigue                      |           |              |                           |
|         |             |     | July 1    | No                           | Negative  |              |                           |
|         |             |     | July 4    | No                           | Negative  |              |                           |

a NP: Nasopharyngeal

b Positive; SARS-CoV-2 detected

c Negative; SARS-CoV-2 not detected

d NHL: National Health Laboratory

e DL: Different Laboratory with new NP swab collection
| Age (years) | Sex | Timelines     | Symptoms | NP a Swab | Confirmation | Serology (SARS-CoV-2 IgG) |
|------------|-----|---------------|----------|-----------|--------------|--------------------------|
|            |     | August 15     | No       | Positive  |              | Positive                |
|            |     | August 16     | No       | Positive  |              | Positive                |

a NP: Nasopharyngeal
b Positive; SARS-CoV-2 detected
c Negative; SARS-CoV-2 not detected
d NHL: National Health Laboratory
e DL: Different Laboratory with new NP swab collection

**Second Case**

Patient 2 is a 59-year male with no underlying medical conditions who presented on June 16 for COVID-19 testing after developing flu-like illness symptoms. The test result came out positive and was confirmed by the NHL (Table 1). A week later, the patient’s health started to improve, and symptoms began to disappear gradually. On July 1 and 4, two consecutive follow-up tests were done, and both results were negative for SARS-CoV-2, which suggested that the patient was cured. At the beginning of August, some of the patient’s family members were infected with SARS-CoV-2 experienced flu-like symptoms such as fever, fatigue, and headache. Although the patient himself did not experience any symptoms, he decided to do a cautionary SARS-CoV-2 test on mid-August, and it revealed a positive result which was also confirmed on a subsequent NP swab collection. Furthermore, we performed IgG assay at that time, which came back positive (titer of 5.7 AU/mL), confirming the presence of SARS-CoV-2 antibodies.

**Discussion And Conclusion**

We report here two cases of healthy adults who had two episodes of possible COVID-19 infection. Interestingly, in one case, the symptomatic patient with recurrence of positive SARS-CoV-2 occurred after three months of the initial infection that did not trigger a protective immune response. In the other case, asymptomatic patient with recurrence of positive SARS-CoV-2 occurred within three months of the initial infection.

Recently, Yao et al. demonstrated that SARS-CoV-2 viral particles remain in previously positive patients’ lungs whose NP swabs results were negative three times consecutively; this suggests that SARS-CoV-2 virus may not be eliminated when the symptoms disappear [8]. Therefore, there is still a reason to be
cautious, and we need to be aware of recovered patients and their potential infectivity. Interestingly, there have not been any studies demonstrating that recovered patients are infectious.

To our knowledge, our cases are the first to describe positive SARS-CoV-2 viral RNA in recovered COVID-19 patients in the Middle East. According to the Centers for Disease Control and Prevention (CDC), reinfection of SARS-CoV-2 is highly considered in a patient who becomes symptomatic around 90 days after onset of infection and has been in close contact with an infected person, supporting our first case [9]. A similar case presenting recurrence of SARS-CoV-2 has been reported in Hong Kong, bringing more attention lately. To and his colleagues demonstrated that second episode of asymptomatic infection occurred after the first symptomatic episode in an apparently immunocompetent patient [4]. In addition, they confirmed SARS-CoV-2 reinfection by performing whole genome sequencing for the first and second episodes indicating different clades [4]. We assume that the recurrence of COVID-19 is possible due to the presence of nonprotective IgG and recovered patients might be carriers and actively transmitting the virus even after their two negative tests [10, 11]. Thus, gatherings of positive cases are not safe, and there should be an emphasis upon such social practices, and for those in convalescence, we suggest that they undergo regular tests for infectivity assessments.

The presence of SARS-CoV-2 virus appears to be unstable because of the possibility of false-negative results of the molecular test which might be due to fluctuations in the viral load or pre-analytical errors during the sample collection [12]. In our case reports, reducing the chance of false-negative and false-positive results was done by confirming each test result in different laboratory with new NP swab collection. For both cases, first positive test results were confirmed by the NHL, and two consecutive negative tests were done before the patients were considered to be cured. Although these are only two case reports and the evidence is not determinant, it gives insight and encourages future cohort studies.

In conclusion, the global public health is at risk of the possibility of recurrence of SARS-CoV-2 as we exhibited in our case reports, which could contribute to the spread of the virus. Therefore, additional virologic, immunological, and epidemiological studies should be done to have better understanding of SARS-CoV-2 recurrence mechanism.

**Abbreviations**

**SARS-CoV-2**: Severe acute respiratory syndrome coronavirus 2  
**COVID-19**: Coronavirus disease 2019  
**RT-PCR**: Real-time reverse transcriptase-polymerase chain reaction  
**IgG**: Immunoglobin G  
**MOH**: Ministry of Health  
**RNA**: Ribonucleic acid
**Declarations**

**Ethics approval and consent to participate**

Not Applicable.

**Consent of publication**

Written consent was obtained from the patient for publication.

**Availability of data and material**

Derived data are available on reasonable request.

**Competing interests**

The authors have declared that no competing interests exist.

**Funding**

The authors received no specific funding for this work.

**Contributions**

Sara Alturaif, Remaaz Alharbi, Abdulaziz Alsadoon, and Meshari Alabdullatif conceptualized and refined research idea, and collected and processed the patients’ samples. Sara Alturaif, Remaaz Alharbi, and Waleed Alqurashi created case report design and wrote the manuscript. Waleed Alqurashi and Meshari Alabdullatif edited the manuscript.

**Corresponding author**

Correspondence to Meshari Alabdullatif.

**Acknowledgements**

Not applicable.

**References**
1. Coronavirus (COVID-19) Cases - Statistics and Research. Our World in Data. Published 2020. Accessed August 13, 2020. https://ourworldindata.org/covid-cases.

2. COVID 19 Dashboard: Saudi Arabia. Published 2020. Accessed August 13, 2020. https://covid19.moh.gov.sa/.

3. Kiyuka PK, Agoti CN, Munywoki PK, et al. Human Coronavirus NL63 Molecular Epidemiology and Evolutionary Patterns in Rural Coastal Kenya. J Infect Dis. 2018;217:1728-1739.

4. To KK-W, Hung IF-N, Ip JD, et al. COVID-19 re-infection by a phylogenetically distinct SARS-coronavirus-2 strain confirmed by whole genome sequencing. Clin Infect Dis. 2020. doi:10.1093/cid/ciaa1275.

5. MOH Publications - COVID-19 Guidelines. Accessed August 14, 2020. https://www.moh.gov.sa/en/Ministry/MediaCenter/Publications/Pages/covid19.aspx.

6. Saudi MoH Protocol for Patients Suspected of/Confirmed with COVID-19. Accessed August 13, 2020. https://www.moh.gov.sa/Ministry/MediaCenter/Publications/Documents/MOH-therapeutic-protocol-for-COVID-19.pdf.

7. Deeks JJ, Dinnes J, Takwoingi Y, et al. Antibody tests for identification of current and past infection with SARS-CoV-2. Cochrane Database Syst Rev. 2020. doi:10.1002/14651858.CD013652.

8. Yao X-H, He Z-C, Li T-Y, et al. Pathological evidence for residual SARS-CoV-2 in pulmonary tissues of a ready-for-discharge patient. Cell Research. 2020;30:541-543.

9. Test for Past Infection | CDC. Published 2020. Accessed September 8, 2020. https://www.cdc.gov/coronavirus/2019-ncov/testing/serology-overview.html.

10. Lan L, Xu D, Ye G, et al. Positive RT-PCR Test Results in Patients Recovered From COVID-19. JAMA. 2020;323:1502-1503.

11. Loconsole D, Passerini F, Palmieri VO, et al. Recurrence of COVID-19 after recovery: a case report from Italy. Infection. 2020. doi:10.1007/s15010-020-01444-1.

12. Xiao AT, Tong YX, Zhang S. False negative of RT-PCR and prolonged nucleic acid conversion in COVID-19: Rather than recurrence. Journal of Medical Virology. 2020. doi:10.1002/jmv.25855.